Menu Search
Equities

Adaptive Biotechnologies Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1HM:FRA

Adaptive Biotechnologies Corp

Actions
  • Price (EUR)13.30
  • Today's Change-1.15 / -7.93%
  • Shares traded2.34k
  • 1 Year change+73.90%
  • Beta2.1925
Data delayed at least 15 minutes, as of Feb 06 2026 17:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

  • Revenue in USD (TTM)252.75m
  • Net income in USD-79.61m
  • Incorporated2009
  • Employees619.00
  • Location
    Adaptive Biotechnologies Corp1165 Eastlake Ave ESEATTLE 98109United StatesUSA
  • Phone+1 (206) 659-0067
  • Fax+1 (206) 659-0667
  • Websitehttps://www.adaptivebiotech.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.